Karyopharm Therapeutics (NASDAQ:KPTI) Raised to “Hold” at Wall Street Zen

Karyopharm Therapeutics (NASDAQ:KPTI) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other research analysts have also recently weighed in on KPTI. Robert W. Baird dropped their price objective on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, October 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Karyopharm Therapeutics in a report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price objective (down previously from $15.00) on shares of Karyopharm Therapeutics in a research note on Thursday, October 9th. HC Wainwright raised shares of Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Monday, October 13th. Finally, Royal Bank Of Canada lowered their price target on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating for the company in a report on Tuesday. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Karyopharm Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $15.40.

Karyopharm Therapeutics Trading Down 1.1%

Shares of KPTI stock opened at $5.16 on Friday. The stock has a 50 day simple moving average of $6.18 and a 200-day simple moving average of $5.40. Karyopharm Therapeutics has a 12-month low of $3.51 and a 12-month high of $14.24. The company has a market cap of $44.74 million, a price-to-earnings ratio of -0.36 and a beta of 0.35.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($3.82) EPS for the quarter, missing the consensus estimate of ($3.30) by ($0.52). The company had revenue of $44.04 million for the quarter, compared to analysts’ expectations of $39.56 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Baird Financial Group Inc. purchased a new stake in Karyopharm Therapeutics during the second quarter valued at about $45,000. XTX Topco Ltd purchased a new position in shares of Karyopharm Therapeutics in the 2nd quarter worth about $56,000. Silverback Asset Management LLC lifted its stake in shares of Karyopharm Therapeutics by 40.0% in the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after purchasing an additional 20,000 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Karyopharm Therapeutics by 26.8% during the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after purchasing an additional 35,626 shares during the period. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth about $163,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).